Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DL76CW
|
|||
| Drug Name |
EP-100
|
|||
| Drug Type |
Peptide
|
|||
| Indication | Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183] | Phase 2 | [1] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1 | [2] | ||
| Company |
Esperance Pharmaceuticals
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | ClinicalTrials.gov (NCT00949559) Pharmacodynamics (PD) and Pharmacokinetics (PK) Study of EP-100 in Advanced Solid Tumors. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.